

Emiliano Cocco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3064382/publications.pdf>

Version: 2024-02-01

18
papers

1,938
citations

687363

13
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

3331
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. <i>Nature Communications</i> , 2022, 13, 1450.	12.8	47
2	The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. <i>Cancer Research</i> , 2022, 82, 2269-2280.	0.9	6
3	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , 2021, 11, 126-141.	9.4	34
4	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. <i>Npj Breast Cancer</i> , 2021, 7, 124.	5.2	7
5	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 1624-1632.	7.0	103
6	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 534-550.e9.	16.8	67
7	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	21.4	140
8	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	12.8	37
9	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
10	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. <i>Nature Medicine</i> , 2019, 25, 1422-1427.	30.7	144
11	Whole-exome sequencing of cervical carcinomas identifies activating <i>ERBB2</i> and <i>PIK3CA</i> mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
12	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. <i>Cell Reports</i> , 2019, 27, 294-306.e5.	6.4	49
13	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
14	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019, 153, 158-164.	1.4	13
15	Neratinib is effective in breast tumors bearing both amplification and mutation of <i>ERBB2</i> (HER2). <i>Science Signaling</i> , 2018, 11, .	3.6	53
16	NTRK fusion-positive cancers and TRK inhibitor therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 731-747.	27.6	975
17	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4845-4853.	7.0	18
18	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. <i>Blood</i> , 2017, 130, 794-794.	1.4	0